NCT06708741 Regime for Vitamin D Maintenance in Post-Operative Patients
| NCT ID | NCT06708741 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sengkang General Hospital |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 100 participants in total. It began in 2026-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vitamin D plays a significant part calcium and phosphate haemostasis, thus, intrinsically critical for bone health. Increasing evidence also reveal that insufficient serum vitamin D levels also result in poor muscle health with such individuals having a compromised muscle building potential (4 times slower muscle building). Muscle health is a critical component of a post-surgical patient recovery, with impaired muscle function leading to reduced functional ability, resulting in a poorer quality of life. Poor muscle health also has negative repercussion on survivability, with reduced overall, and disease-specific survival, especially shown in cancer patients. Thus, maintenance of vitamin D levels post-surgery may be more critical than previously thought.
Eligibility Criteria
Inclusion Criteria: * Serum 25-hydroxyvitamin D levels between 30-50ng/ml at 4-6 weeks after operation * aged 21-65 years * ability to provide informed consent * accepts to take vitamin D supplements post-operatively and * have their serum vitamin D levels checked periodically. Exclusion Criteria: * They have undergone minor procedures (Table code \<4a) * have a history of chronic kidney disease/end staged renal failure * have previous history of ureteric/kidney stones * known hyperparathyroidism * are non-ambulatory independently * have had known allergies to the commercially available high dose vitamin D formulations. * Vulnerable personnel would be excluded from the study
Contact & Investigator
Frederick H Koh, FRCS, PhD
PRINCIPAL INVESTIGATOR
Sengkang General Hospital
Frequently Asked Questions
Who can join the NCT06708741 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 65 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06708741 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 100 participants.
Is NCT06708741 currently recruiting?
Yes, NCT06708741 is actively recruiting participants. Contact the research team at frederick.koh.h.x@singhealth.com.sg for enrollment information.
Where is the NCT06708741 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06708741 clinical trial?
NCT06708741 is sponsored by Sengkang General Hospital. The principal investigator is Frederick H Koh, FRCS, PhD at Sengkang General Hospital. The trial plans to enroll 100 participants.